智通财经APP获悉，香港联交所最新资料显示，10月6日，主席兼执行董事蔡东晨增持石药集团 (01093)200万股，每股作价为9.645港元，总金额为1929万港元。增持后最新持股数目约为28.37亿股， 最新持股比例为24.62%。 ...

Group 1 - The latest shareholder equity disclosure for Lion Rock Group (01127) and CSPC Pharmaceutical Group (01093) was conducted on October 6, 2025 [1] - Liu Zhujian increased his holdings in Lion Rock Group from 360 million shares to 362 million shares, representing a holding percentage increase from 46.70% to 46.99% [2] - Cai Dongchen slightly increased his holdings in CSPC Pharmaceutical Group from 2.834 billion shares to 2.835 billion shares, with a holding percentage increase from 24.59% to 24.61% [2]

| 股份代號: | 01093 | | --- | --- | | 上市法國名稱: | 石藥集國有限公 | | 日期 (日 / 月 / 年): | 06/09/2025 - 06 | 格隆汇10月6日丨根据联交所最新权益披露资料显示，2025年10月2日-10月3日，石药集团(01093.HK)获执行董事兼主席蔡东晨在场内以每股均价9.6238- 9.6383港元合计增持725.4万股，涉资约6989.8万港元。 增持后，蔡东晨最新持股数目为2,835,118,670股，持股比例由24.54%上升至24.61%。 | 表格序號 | 大股東/董事/最高行政人員名稱 作出披露的 買入 / 賣出或涉及的股每股的平均價 | | | | | 持有權益的股份數目 佔已發行的 有關事件的日 | | | --- | --- | --- | --- | --- | --- | --- | --- | | | | 原大 | 份數目 | | | (請參閱上述*註解)有投票權股 (日 / 月 / 年) | | | | | | | | | 份自分比 | | | | | | | | | ( % ) | | | DA20251003E00 ...

Core Insights - The latest shareholder equity disclosures for Electronic Trading Group (08036), Shenkong Holdings (00829), and CSPC Pharmaceutical Group (01093) were made on October 3, 2025 [1] Group 1: Electronic Trading Group (08036) - Shareholder 聂凡淇 reduced holdings from 98.04 million shares to 85.22 million shares, representing a decrease in ownership from 7.97% to 6.93% [2] - Financial Data Technologies Limited also reported the same reduction in holdings, confirming the decrease in ownership percentage [2] Group 2: Shenkong Holdings (00829) - Shareholder 周亚仙 increased holdings from 1.627 billion shares to 1.631 billion shares, resulting in a slight increase in ownership from 50.37% to 50.50% [2] Group 3: CSPC Pharmaceutical Group (01093) - Shareholder 蔡东晨 increased holdings from 2.828 billion shares to 2.834 billion shares, leading to a rise in ownership from 24.54% to 24.59% [2]

香港联交所最新资料显示，10月2日，主席兼执行董事蔡东晨增持石药集团(01093)600万股，每股作价 为9.6383港元，总金额为5782.98万港元。增持后最新持股数目约为28.34亿股，最新持股比例为 24.59%。 ...

智通财经APP获悉，香港联交所最新资料显示，10月2日，主席兼执行董事蔡东晨增持石药集团 (01093)600万股，每股作价为9.6383港元，总金额为5782.98万港元。增持后最新持股数目约为28.34亿 股，最新持股比例为24.59%。 ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 | 截至月份: | 2025年9月30日 | 狀態: 新提交 | | --- | --- | --- | | 致：香港交易及結算所有限公司 | | | | 公司名稱: | 石藥集團有限公司 | | | 呈交日期: | 2025年10月2日 | | | I. 法定/註冊股本變動 不適用 | | | FF301 第 1 頁 共 10 頁 v 1.1.1 FF301 II. 已發行股份及/或庫存股份變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 01093 | 說明 | | | | | | | | | 已發行股份（不包括庫存股份）數目 | | 庫存股份數目 | | 已發行股份總數 | | | 上月底結存 | | | 11,521,951,732 | | 0 | | 11,521,951,732 | | 增加 / 減少 (-) | | | 50 ...

Major Events - Jinye International Group (08549) plans to issue 100 million shares from September 30 to October 6 [1] - Zhida Technology (02650) intends to globally issue 5.9789 million shares, expecting to list on October 10 [1] - CSPC Pharmaceutical Group (01093) received clinical trial approval for SYH2070 injection (double-stranded small interfering RNA drug) in China [1] - Mixue Group (02097) plans to invest in a fresh beer product company to seize opportunities in the fresh beer industry [1] - Shangshan Gold (01939) proposes a placement at a discount of approximately 19.88%, aiming to raise about HKD 245.8 million [1] - GC Construction (01489) sees a change in controlling interest with a buyout offer at a discount of about 45.91%, resuming trading on October 2 [1] - Times Financial Services Group (00510) major shareholder plans to sell some shares, resuming trading on October 2 [1] - Huajian Medical (01931) confidentially submitted an F-1 registration statement for a dual listing in the U.S. [1] - Ding Shi Capital (00804) intends to acquire 100% equity of a distressed asset disposal business, actively entering the distressed asset market [1] - Chuangmeng Tiandi (01119) plans to issue a total of 236 million shares [1] - Zhaogang Group-W (06676) intends to conduct a share buyback [1] - Daren International (01957) is exploring the possibility of acquiring up to 100 bitcoins [1] - Sihuan Pharmaceutical (00460) received approval from the National Medical Products Administration for its self-developed L-carnosine composite solution water light needle "Frozen Beauty" [1] Bonds and Notes - Minmetals Resources (01208) plans to issue USD 500 million zero-coupon convertible bonds maturing in 2030 [2] Share Buybacks - Tencent Holdings (00700) repurchased approximately 832,000 shares for about HKD 551 million on September 30 [2] - Midea Group (00300) spent approximately CNY 146 million to repurchase 2.0015 million A-shares on September 30 [2] - Anta Sports (02020) repurchased approximately 1.000 million shares for about HKD 99.87 million on September 30 [2] - SF Holding (06936) repurchased approximately 937,600 A-shares for about CNY 37.78 million on September 30 [2] - HSBC Holdings (00005) repurchased approximately 2.1133 million shares for about GBP 22.07 million on September 29 [2] Operating Performance - BYD Company (01211) reported approximately 3.2601 million new energy vehicle sales in the first nine months, a year-on-year increase of 18.64% [2] - Geely Automobile (00175) reported total vehicle sales of 273,100 units in September, a year-on-year increase of approximately 35% [2] - Great Wall Motors (02333) reported total vehicle sales of approximately 133,600 units in September, a year-on-year increase of 23.29% [2] - NIO Inc. (09866) delivered 34,749 vehicles in September, setting a new monthly record with a year-on-year increase of 64.1% [2] - Li Auto (02015) delivered 33,951 new vehicles in September [2]

格隆汇9月30日丨石药集团(01093.HK)公告，于2025年9月30日，公司间接非全资附属公司石药创新董事 会已批准于联交所主板的H股建议上市。预期紧随H股建议上市完成后，石药创新将仍为公司间接附属 公司。现时预期H股建议上市将涉及透过石药创新新H股于联交所主板首次公开发售进行提呈发售以供 认购，占紧随H股建议上市完成后石药创新经扩大已发行股本不超过10%(假设超额配股权未获行使)。 ...

Core Viewpoint - The company, Shijiazhuang Pharmaceutical Group, has announced the approval of a proposed listing of its indirect non-wholly owned subsidiary, Shijiazhuang Innovation, on the Hong Kong Stock Exchange (HKEX) main board, expected to be completed by September 30, 2025 [1] Summary by Relevant Sections - **Proposed Listing**: The board of Shijiazhuang Innovation has approved the proposal for H-share listing on the HKEX [1] - **Ownership Impact**: Following the completion of the H-share listing, the company's ownership percentage in Shijiazhuang Innovation is expected to decrease by approximately 8.46%, resulting in the company holding about 66.20% of the subsidiary's equity [1] - **Share Issuance**: The proposed listing includes the issuance of shares and an over-allotment option, which, if fully exercised, will affect the company's equity stake [1]